planes de pago
¿Quieres analizar varias empresas a la vez? Los planes de pago te permiten comparar hasta 5 acciones lado a lado.
Regístrate
C
445680
vs
K
KOSPI 200
En los últimos 12 meses, Curiox BioSystems Co Ltd ha quedado por detrás de KOSPI 200, con una rentabilidad de -23% frente a un crecimiento de +40% de KOSPI 200.
Rendimiento de las acciones
445680 vs KOSPI 200
Diferencia de rendimiento
445680 vs KOSPI 200
Rendimiento por año
445680 vs KOSPI 200
Compara la rentabilidad de la acción con su índice de referencia y sus competidores. Obtén información sobre su rendimiento relativo a lo largo del tiempo.
Rendimiento de los competidores
Curiox BioSystems Co Ltd vs pares
Curiox BioSystems Co Ltd
Vista general
Curiox BioSystems makes laboratory tools that help scientists prepare biological samples for testing. Its main products are automated systems and consumables for washing, staining, and handling cells and other delicate samples in research and clinical labs. The company’s equipment is designed to reduce manual sample-prep steps, which can save time and help make lab results more consistent. The company sells mainly to biotech and pharmaceutical companies, research labs, hospitals, and other life-science organizations that need reliable sample preparation for experiments and diagnostics. It makes money by selling its instruments and by supplying the consumables that work with those instruments, which creates repeat business after the initial equipment sale. That model ties customers into its installed base because the tools and disposable parts are designed to work together. What makes Curiox different is its role in the sample-preparation part of the lab workflow, not in the final test itself. It sits upstream of analysis, where small errors can affect the quality of downstream results. By focusing on gentler, more automated sample handling, the company aims to replace manual lab work with a more standardized process that fits both high-throughput research and clinical testing.